Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids.
Journal
STAR protocols
ISSN: 2666-1667
Titre abrégé: STAR Protoc
Pays: United States
ID NLM: 101769501
Informations de publication
Date de publication:
19 06 2020
19 06 2020
Historique:
entrez:
28
10
2020
pubmed:
29
10
2020
medline:
29
10
2020
Statut:
epublish
Résumé
This protocol describes the isolation, handling, culture of, and experiments with human colon stem cell organoids in the context of cystic fibrosis (CF). In human colon organoids, the function of cystic fibrosis transmembrane conductance regulator (CFTR) protein and its rescue by CFTR modulators can be quantified using the forskolin-induced swelling assay. Implementation procedures and validation experiments are described for six CF human colon organoid lines, and representative CFTR genotypes are tested for basal CFTR function and response to CFTR-modulating drugs. For complete details on the use and execution of this protocol, please refer to Dekkers et al (2016) and Berkers and van Mourik (2019).
Identifiants
pubmed: 33111074
doi: 10.1016/j.xpro.2020.100019
pii: S2666-1667(20)30006-X
pmc: PMC7580120
doi:
Substances chimiques
Colforsin
1F7A44V6OU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
100019Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
J.F.D. is an inventor on a patent related to the organoid technology. M.A.A. reports grants from Gilead Pharmaceuticals, Vertex Pharmceuticals, Proteostasis Therapeutics and personal fees from Vertex Pharmceuticals and PTC Pharmaceuticals outside the submitted work. K.B. reports consultancy work for CHIESI, grants from VERTEX, advisory board meetings for PROTEOSTASIS and ELOXX, grants from and advisory board meetings for GALAPAGOS, and advisory board meetings for TRANSLATE BIO outside the submitted work. R.V. is CEO of Hubrecht Organoid Technology, which provides organoid services to companies. C.K.E. reports grants from GSK, Nutricia, TEVA, Gilead, Vertex, ProQR, Proteostasis, Galapagos NV, and Eloxx outside the submitted work and has a patent 10006904 with royalties paid. J.M.B. is inventor on a patent related to CFTR function measurements in organoids and has received financial royalties. He also participates in industry-sponsored clinical trials (Galapagos NV, Vertex Pharmaceuticals, Proteostasis, Eloxx Pharmaceuticals) and has received travel reimbursements and speaker’s fees. The other authors have nothing to disclose.
Références
Nat Med. 2013 Jul;19(7):939-45
pubmed: 23727931
PLoS Biol. 2018 Jul 3;16(7):e2005970
pubmed: 29969450
BMC Gastroenterol. 2013 May 20;13:91
pubmed: 23688510
Cell Rep. 2019 Feb 12;26(7):1701-1708.e3
pubmed: 30759382
Sci Transl Med. 2016 Jun 22;8(344):344ra84
pubmed: 27334259
J Vis Exp. 2017 Feb 11;(120):
pubmed: 28287550